Population pharmacokinetic‐pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine‐refractory differentiated thyroid cancer (RR‐DTC)

• Váldodahkkit: Oneeb Majid (Dahkki), Seiichi Hayato (Dahkki), Sree Harsha Sreerama Reddy (Dahkki), Bojan Lalovic (Dahkki), Taro Hihara (Dahkki), Taisuke Hoshi (Dahkki), Yasuhiro Funahashi (Dahkki), Jagadeesh Aluri (Dahkki), Osamu Takenaka (Dahkki), Sanae Yasuda (Dahkki), Ziad Hussein (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Wiley, 2024-06-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Abstract Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor targeting vascular endothelial growth factor (VEGF) receptors 1-3, fibroblast growth factor (FGF) receptors 1-4, platelet‐derived growth factor receptor‐α (PDGFRα), KIT, and RET that have been implicated in pathogenic angiogenesis, tu...